MX2020001451A - Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico. - Google Patents
Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.Info
- Publication number
- MX2020001451A MX2020001451A MX2020001451A MX2020001451A MX2020001451A MX 2020001451 A MX2020001451 A MX 2020001451A MX 2020001451 A MX2020001451 A MX 2020001451A MX 2020001451 A MX2020001451 A MX 2020001451A MX 2020001451 A MX2020001451 A MX 2020001451A
- Authority
- MX
- Mexico
- Prior art keywords
- oncolytic virus
- antibody
- negative breast
- triple negative
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente, se proporcionan métodos de tratamiento de un sujeto con cáncer de mama triple negativo o cáncer colorrectal. En ejemplos de modalidades, el método comprende administrar al sujeto una combinación de un virus oncolítico, tal como talimogén laherparepvec, y un anticuerpo anti-PD-L1, tal como atezolizumab. En ejemplos de aspectos, el virus oncolítico se administra al sujeto en una dosis inicial seguida por una segunda dosis, donde la dosis inicial es menor que la segunda dosis. En ejemplos de aspectos, el virus oncolítico se administra a nivel intrahepático al sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542046P | 2017-08-07 | 2017-08-07 | |
| PCT/US2018/045328 WO2019032431A1 (en) | 2017-08-07 | 2018-08-06 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER COMPRISING HEPATIC METASTASES BY ANTI-PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001451A true MX2020001451A (es) | 2020-08-06 |
Family
ID=63556436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001451A MX2020001451A (es) | 2017-08-07 | 2018-08-06 | Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200254037A1 (es) |
| EP (1) | EP3664844A1 (es) |
| JP (1) | JP2020530003A (es) |
| CN (1) | CN111246883A (es) |
| AR (1) | AR112405A1 (es) |
| AU (1) | AU2018314227A1 (es) |
| CA (1) | CA3071599A1 (es) |
| MA (1) | MA49849A (es) |
| MX (1) | MX2020001451A (es) |
| TW (1) | TW201912173A (es) |
| WO (1) | WO2019032431A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL259588B2 (en) | 2016-01-08 | 2023-09-01 | Hoffmann La Roche | Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3 |
| BR112021017551A2 (pt) * | 2019-03-05 | 2021-11-09 | Amgen Inc | Uso de vírus oncolíticos para o tratamento de câncer |
| WO2022028608A1 (zh) * | 2020-08-07 | 2022-02-10 | 百奥泰生物制药股份有限公司 | 抗pd-l1抗体及其应用 |
| US20230338537A1 (en) * | 2020-08-14 | 2023-10-26 | Mayo Foundation For Medical Education And Research | Methods and materials for tissue ablation |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342776A (en) | 1979-11-05 | 1982-08-03 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| JPS5839685A (ja) | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体及びその製造法 |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| CA1264738A (en) | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| ATE211142T1 (de) | 1989-09-15 | 2002-01-15 | Res Triangle Inst | Verfahren zur herstellung von 10,11-methylendioxy-20(rs)-camptothecin und 10,11-methylendioxy-20(s)-camptothecin-analog |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| FR2707988B1 (fr) | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| CA2346866A1 (en) | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
| EP1141338A4 (en) | 1998-12-31 | 2002-09-25 | Arch Dev Corp | RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES |
| AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| EP1252323B1 (en) | 2000-01-21 | 2005-12-07 | BioVex Limited | Virus strains for the oncolytic treatment of cancer |
| CA2441663C (en) | 2001-03-27 | 2013-01-22 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
| US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| KR101782570B1 (ko) | 2008-12-09 | 2017-09-27 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| AU2012245477C1 (en) | 2011-04-20 | 2017-06-15 | Medimmune, Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
| US20130028882A1 (en) | 2011-07-07 | 2013-01-31 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| WO2016009017A1 (en) * | 2014-07-16 | 2016-01-21 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| AU2017207532A1 (en) * | 2016-01-11 | 2018-08-16 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| WO2018170133A1 (en) * | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
-
2018
- 2018-08-06 CN CN201880065031.1A patent/CN111246883A/zh active Pending
- 2018-08-06 CA CA3071599A patent/CA3071599A1/en not_active Abandoned
- 2018-08-06 AR ARP180102234 patent/AR112405A1/es unknown
- 2018-08-06 JP JP2020506208A patent/JP2020530003A/ja active Pending
- 2018-08-06 WO PCT/US2018/045328 patent/WO2019032431A1/en unknown
- 2018-08-06 MX MX2020001451A patent/MX2020001451A/es unknown
- 2018-08-06 MA MA049849A patent/MA49849A/fr unknown
- 2018-08-06 EP EP18768988.0A patent/EP3664844A1/en not_active Withdrawn
- 2018-08-06 AU AU2018314227A patent/AU2018314227A1/en not_active Abandoned
- 2018-08-06 TW TW107127241A patent/TW201912173A/zh unknown
- 2018-08-06 US US16/637,600 patent/US20200254037A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020530003A (ja) | 2020-10-15 |
| MA49849A (fr) | 2020-06-17 |
| WO2019032431A1 (en) | 2019-02-14 |
| AR112405A1 (es) | 2019-10-23 |
| AU2018314227A1 (en) | 2020-02-06 |
| AU2018314227A8 (en) | 2020-10-08 |
| EP3664844A1 (en) | 2020-06-17 |
| TW201912173A (zh) | 2019-04-01 |
| CA3071599A1 (en) | 2019-02-14 |
| CN111246883A (zh) | 2020-06-05 |
| US20200254037A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001451A (es) | Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico. | |
| MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
| WO2017176628A8 (en) | Methods for solid tumor treatment | |
| NZ631197A (en) | Anti sez6 antibodies and methods of use | |
| MA39906A (fr) | Polythérapies pour le traitement du cancer | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2018005071A (es) | Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. | |
| MX2023006304A (es) | Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central. | |
| EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
| NZ760459A (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| WO2019103449A3 (ko) | 항암바이러스의 간동맥 투여를 이용한 간암 치료방법 | |
| EP2786764A3 (en) | Combination therapy using anti-c-met antibody and sorafenib | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX2022006891A (es) | Terapia combinada con liv1-adc y antagonista de pd-1. |